Wall Street Zen Upgrades Nanovibronix (NASDAQ:FEED) to Hold

Nanovibronix (NASDAQ:FEED) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings assumed coverage on shares of Nanovibronix in a report on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Nanovibronix Price Performance

Shares of Nanovibronix stock opened at $1.96 on Friday. The firm has a market cap of $2.14 million, a PE ratio of -0.05 and a beta of 2.09. Nanovibronix has a twelve month low of $0.99 and a twelve month high of $162.50. The business has a 50-day simple moving average of $2.31.

Insider Buying and Selling

In other news, major shareholder Christian Michael Glibert acquired 240,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average price of $2.67 per share, with a total value of $640,800.00. Following the completion of the transaction, the insider directly owned 240,000 shares of the company’s stock, valued at $640,800. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is currently owned by company insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.